Avtor/Urednik		Černe, Andreja
Naslov		Vpliv zaviralcev trombocitnih receptorjev GP IIb/IIIa na nastanek žilnih zapletov pri intervencijskih posegih na srcu
Tip		monografija
Kraj izdaje		Ljubljana
Založnik		Medicinska fakulteta
Leto izdaje		1998
Obseg		str. 60
Jezik		slo
Abstrakt		Background and aims of tlze study Chimeric monoclonal antibodies (c7E3) against the platelet glycoprotein receptor GP IIb/IIIa inhibit platelet aggregation and exert potent antithrombotic effects. In clinical trials, c7E3 markedly reduced the incidence of ischemic complications after percutaneous transluminal coronary angioplasty (PTCA), but increased the incidence of bleeding events, particularly at the femoral access site. Vascular complications after PTCA in patients receiving c7E3 have not yet been systematically evaluated. The aims of our study were: 1) to determine whether treatment with c7E3 increases the incidence of vascular complications, 2) to identify risk factors for vascular complications in patients receiving c7E3 after PTCA, and 3) to provide the most appropriate treatment of the detected vascular complications. Patients and methods This prospective case-controlled study involved 60 consecutive patients receiving c7E3 (ReoProTM) in a bolus and by infusion because of high-risk elective or urgent PTCA (ReoPro group). The control group consisted of 60 consecutive patients undergoing PTCA without the use of c7E3. The groups were matched for their demographic characteristics, procedural protocol and other drugs likely to affect haemostasis. The vascular access site was evaluated clinically and ultrasonographically within 12 hours of the completion of the procedure. Laboratory tests were performed prior to and 12 hours after PTCA. Bleeding complications were classified as major and minor according to the TIMI criteria (Thrombolysis in Myocardial Infarction). Thrombocytopenia was defined as a drop in platelet count lesser than 150x10/9/L, or greater than 40% within 12 hours of the initiation of c7E3 treatment. Vascular complications were managed by systemic erythrocyte or platelet substitution and locally by ultrasonographically guided external compression or surgical correction of the affected vessel wall. (trunc. at 2000 chars)
Deskriptorji		ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY CATHETERIZATION, PERIPHERAL PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX FEMORAL ARTERY VASCULAR DISEASES ADULT MIDDLE AGE AGED HEMATOMA ANEURYSM, FALSE ARTERIOVENOUS FISTULA PLATELET AGGREGATION INHIBITORS BLOOD SUBSTITUTES CASE-CONTROL STUDIES THROMBOCYTOPENIA